Loading organizations...
§ Private Profile · San Diego, CA, USA
Clinical-stage biopharmaceutical company developing biomarker-driven precision medicines for oncology and psychiatric disorders.
Denovo Biopharma is a clinical-stage biopharmaceutical company based in San Diego, California, that develops biomarker-driven precision medicines, including gene therapies and small molecule drugs for oncology and neurological disorders. The privately held enterprise operates with approximately 25 employees and manages a clinical pipeline of eight therapeutic assets targeting severe conditions such as depression, Alzheimer's disease, and glioblastoma. To date, the organization has raised approximately $180 million in funding from over 30 healthcare venture capital and private equity firms, while also securing an $11.8 million grant from the California Institute for Regenerative Medicine. Its strategic expansion includes the 2020 acquisition of the DB107 gene therapy from Tocagen, supported by an advisory and leadership team with prior executive experience at Plexxikon, Poseida, and Pfizer. Denovo Biopharma was founded in 2012 by Dr. Wen Luo.
Denovo Biopharma has raised $54.5M across 2 funding rounds.
Denovo Biopharma has raised $54.5M in total across 2 funding rounds.
Denovo Biopharma has raised $54.5M across 2 funding rounds. Most recently, it raised $12.0M Other Equity in May 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 7, 2024 | $12M Venture Round | California Institute For Regenerative Medicine | — | Announced |
| Oct 31, 2019 | $42.5M Series B | — | Sangel Capital | Announced |
Denovo Biopharma has raised $54.5M in total across 2 funding rounds.
Denovo Biopharma's investors include California Institute for Regenerative Medicine, Sangel Capital.